These mechanistic insights strengthen the proposition that CYSLTR1 holds substantial promise as a therapeutic target, not only for psoriasis but also for autoimmune diseases underpinned by the dysregulation of Th17 cells. The gene discussed is CYSLTR1; the disease is autoimmune disease.